Member Info for AB124

Wildforce,
" .. or do you think they just agree to shoot anything into people ?"
Isn't that what trials are for?

Looks like a very encouraging move forward.

Hasiba,
So who else was going to take on the role of CEO?
Can't imagine that the CSO was too pleased to be faced with a return to her previous incarnation but this time without the assistance of a Co CEO.
S[preading resources a little thin aren't they?
AIMO

Moonparty
I'm not suggesting anything underhand. The BOD of Scancell were thrown a lifeline last year.
They took it (because due to inertia on their timescales for trials etc) they had run out of funds (and to some degree credibility).
That lifeline gave them two years to use the money they got to reverse the rot and get commercial.
One year later (and halfway through their timeline) they've just lost the CEO and a previous encumbent has taken the post back.
It doesn't take an Einstein to work out that with the CLNs in place IIs her can do just what they like.
One of the things that IIs do like is making a profit on their Capital.
If that means pursuing a different line with an investment before their capital is threatened what should they do?
They live or die by performance figures.
Many PIs in Scancell have a more than abysmal performance on their capital invested here (some for nearly ten years). Any fund manager who had done anything so ridiculous might have lasted a couple of years at best, but they'd be driving courier vans by now.
So, who would I look at to see what might happen (and how that might be facilitated)?
Moonparty, thanks for the discussion. You have been polite and accomodating.
It's been a pleasure to discuss things with you.
Thanks for that opportunity.
As I think we agree, only time will tell what transpires here, but FWIW I want to get lots and lots of money for my shares. Anything else would have been a daft reason to stay here.... but I'm trying to be realistic in my expectations.
Hopes are a different matter.
I would like the end result to be a triumph of hope over expectations but then, we all have to live in the real world.
Again, thanks for the discussion.
AIMO

Ratcliffewriter
Your response in your 15.22 is why you have been sitting waiting here whilst the likes of RM and Vulpes have been making mega bucks over the same period.
Let's see what happens then.
Thanks for your contribution.
AIMO

Moonparty
Don't think so.
If Scancell's not going great guns towards GBP1+/ share what price do you think it'll take to get the IIs who have averages at much lower even than now's 20p to get out whilst taking their Loan cash back as well? Don't forget the CLNS mature in 2022 so they won't want to lose the edge it gives them. How many PIs would be daft enough to turn down an offer of (Say) 50p+, chances are they'd be taken out anyway because the IIs would (probably) go with the T/O profit and move on.
The PIs here have no control over their future in SCLP any more. They might get lucky with the IIs agreeing with them but I wouldn't bet on it.
So what ever pPI is relying on here is a sudden and dramatic turn in the BOD's effectiveness in getting (even a) deal.
Well, the third CEO's just gone and one of the first two is back.... let's see.
AIMO

Moonparty.
We'll have to wait and see what happens.
Fingers crossed.
AIMO (as for the last post).

Moonparty
You've made me think about this, and you make a very good point. That is, if we approach November next year and commercialisation is not happening, it would make a great deal of sense for the CLN holders to "Stop the Rot" and actually get Scancell sold whilst still keeping their capital intact, because as others have pointed out earlier here today, there will be cash left in the coffers (if the 2 to 3 years figure is to be believed).
In that way, CLN holders get their money back, they also benefit through their low sp av as well as having sufficient control to deliver Scancell to a suitor (who will not be bidding top dollar because the road to monetisation is not clear).
People pooh pooh a "lowball" offer, but due to the structure of the funding that is precisely the risk here. PI have given up their say in the company by voting for the October cash raising last year.
Unless The BOD here can generate sometihing seriously sensational any talk of mult £ SPs for existing sharholders seems unlikely to be available.
That's why I reckon we've got just over a year to find out.
Those CLNs are significant.... They have put all the cards into their holders' hands.

Moon party
What if the commercialisation is being mishandled?
And the company is doing badly?
Then the CLNs are (I believe) Prior Charge capital, the holder converts sufficient to vote through an offer and then gets paid for the remaining cash liability through the prior charge capital on the breakup of Scancell.
Don't forget CLN note holders are way below the current SP in their existing equity holdings BV wise.
Anyway, lets hope it doesn't come to that!
AIMO

MoonParty
From the offer document last year (available on Scancell's website).
"The New Convertible Loan Notes will be required to be redeemed on the Redemption Date, which will be two years after the date of execution of the Convertible Loan Note Instrument. "
The holders may elect to convert but the Notes are Loans (with 3% nterest).
Source
https://www.scancell.co.uk/Data/Sites/1/media/fininfo/circular-october-2020.pdf
AIMO

MoonParty
I should have said that I, like you, hope the future for Scancell (or whoever holds the various IP/s) is clearly marked out by late 2022.

RuckRover,
"I'd better get some t-shirts reprinted!"
Good Plan!
"The 2022 Pivotal Year T-shirts should be available Q2_23"
How Scancell!!!
Great stuff!

MoonParty
Provided that The lender wants the equity.
It might simply say Repay the loan and the 3% interest.
I'm not saying they will, but I don't believe anyone should assume that a repayment demand is not out of the question, and a prudent CEO will have to consider that contingency. The notes are certainly a way for the holders to maintain a considerable control over the Company and that's why they are there.
AIMO

I think the AGM this year can be considered a pivotal event for Scancell.
The Company will have to give the Shareholders some good news rather than platitudes.
I believe that calendar 2022 will be the Company's Pivotal Year.
AIMO

Ray Pointer
I would mention that the CLNs mature (GBP17.9Mbecome repayable) in November 2022.
This could provide a problem should progress not be seen as the Lender might have wished.
I sincerely hope that we will have reached a short term financial conclusion to that matter before the due date, but I really don't think we can disregard the outstanding item and also with the Increased cash burn since the cash raisings last year things will certainly not be relaxed for 2 -3 years. that Cash burn incidentally will increase with the start of any P2 trials.
As I mentioned before, we are moving rapidly towards the start of the second half of the "New cash rich" Scancell, but we have considerable liabilities to consider sooner than I suspect many appreciate.
Scancell BOD must ensure that there is sufficient commercialisation (or cash promised in the pipeline) to cover the substantial cash requirement to settle the maturing CLNs next year.
So no coasting for Scancell ... we have just over a year!
AIMO

Crumbs,
Thanks for your comments but I wonder why a pharma would not simply bid for Scancell to secure the IP, patents and future expansion and developments of the Pipeline?
Ray Pointer,
Thanks for directing me to your point 3 but I don't purport to undertsand the entire process of the Trials system for a small company like Scancell. I have been wondering whether Scancell could stay in control of its destiny (to P3 and beyond) when it has II with great contacts in the Biopharma market who have a controlling interest in Scancell and who have invested to assist with the progression of the Science from basics to market.
I have generally assumed that the Company (IP) would be attractive to Big Pharma once P1 and initial stages of P2 have been successfully progressed to data which begins to confirm the Anticipated benefits of the science.
RM have a massive holding in Scancell and are not themselves in the business of Biomedicine so as mentioned I'd always assumed they would want out once a suitable "home" could be found for Scancell where the Science can be translated into publicly available therapies as quickly and effectively as possible.
I suppose I am seeing the arrival of RM (and Vulpes) as facilitators of the monetisation of Scancell's IP.
So sorry If I created anger in RP's thoughts but thanks to Crumbs for explaining what I seem to have misunderstood when I see the progression of the pipelines in the context of RM and Vulpes' investments.
AIMO

Ray Pointer
I may have misunderstood your 14.06 but are you thinking of Scancell taking their pipeline all the way to P3?
If so how would they fund that process?
I only ask because I've always thought the IP would have been sold by then (perhaps as soon as shortly after P2 are underway and producing initial Data).
Do you think P3 trials are likely on a go it alone basis for Scancell?

GF
:-)
ATB

GF123
"If he isn’t selling he is lying about saying he was going to sell. I believe he is selling you don’t. So therefore you believe he is lying. It’s binary I’m afraid."
Err NO There's more than one choice so it's NOT Binary.

From DE (NXC) on ADVFN.
NXC - 23 Jun 2021 - 14:46:01 - 40596 of 43222
"...Regarding any overhang I have already said that I will divest my personal holding in an orderly manner - that may take a month that may take 12 months or more who knows ?"
Not Binary he has until June 2022 to sell.
Please withdraw your LIBELLOUS statement abou my saying that DE is Lying. I am emphatically not saying that!

Then you state,
"....I said he had 7m shares. And has sold about half. You believe he had more shares. I don’t believe he had more shares."
Sorry wrong again.
From DE post ADVFN,
NXC - 13 Oct 2020 - 10:33:47 - 32921 of 43222
"......For my part I will be taking up the Open Offer re my holding of approx 9.5m shares .........."
As he was taking up his entitlement under the Funding I assume you agree that he would know that his position was based on 9.5M shares rather than 7M.
So if you read what DE himself posted it looks like your assumptions and accusations are erroneous and frankly based on poor (if not any) research. I have as you advised read the man's own words rather than relying on your assumptions.
I'll await your apologies.

GF123
you posted 13.35
1) "And AB is saying DE is lying. "
2) " I didn’t say he sold 5m shares. You did."

1) I am not saying that DE is lying. Please explain why you say that.

2) GF123 posted
RE: 2 X 100,000 trades + 2 X 96,000 trades...10 Aug 2021 20:15
"I believe he had about 7m shares and I’m
Guessing he has sold half."
That's 3.5M BUT
DE actually has/had about 10M shares. Therefore he has (according to you) sold 5M.
Your response re the Libellous point 1) you make above please.